KIF5B and non-small cell lung carcinoma: RET activation occurs through mutations, gene fusions, and overexpression (Thein et al., 2021), with KIF5B (70%–90%) and CCDC6 (10%–25%) constituting the predominant fusion partners in RET-rearranged NSCLC (Aldea et al., 2023; Hoe and Solomon, 2025).